Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $78,454.50 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 4,825 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $16.26, for a total transaction of $78,454.50. Following the sale, the director now directly owns 3,702,595 shares of the company’s stock, valued at $60,204,194.70. The trade was a 0.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Tyra Biosciences Stock Down 4.8 %

Shares of NASDAQ:TYRA opened at $14.65 on Thursday. The business has a 50 day moving average price of $15.34 and a 200 day moving average price of $19.06. The company has a market cap of $741.29 million, a price-to-earnings ratio of -9.10 and a beta of 1.04. Tyra Biosciences, Inc. has a twelve month low of $12.48 and a twelve month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds have recently added to or reduced their stakes in TYRA. China Universal Asset Management Co. Ltd. acquired a new stake in Tyra Biosciences in the fourth quarter worth about $149,000. JPMorgan Chase & Co. raised its holdings in Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after purchasing an additional 3,896 shares during the period. Franklin Resources Inc. bought a new position in Tyra Biosciences during the third quarter worth about $278,000. Barclays PLC grew its position in shares of Tyra Biosciences by 200.5% in the 3rd quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after purchasing an additional 25,106 shares during the period. Finally, State Street Corp boosted its holdings in shares of Tyra Biosciences by 4.4% in the third quarter. State Street Corp now owns 384,732 shares of the company’s stock valued at $9,045,000 after buying an additional 16,248 shares during the period. Institutional investors own 84.14% of the company’s stock.

Analysts Set New Price Targets

TYRA has been the topic of several research reports. UBS Group began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, January 13th. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.